Close Menu

NEW YORK – Investment bank BTIG on Monday downgraded Fulgent Genetics from a Buy rating to Neutral saying the benefits the firm is seeing from its COVID-19 testing business may not be sustainable.

On Monday, Fulgent raised its full-year revenue guidance for the third time this year, this time to $300 million, which would represent 800 percent year-over-year growth. The Temple City, California firm had increased guidance in August from $120 million to $135 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Centers for Disease Control and Prevention has identified a small group of breakthrough COVID-19 cases, the Wall Street Journal reports.

The New York Times reports that the US Department of Defense is to use genetic genealogy approaches to identify the remains of unknown soldiers.

Vox and Nature discuss the importance of preparing for the next pandemic.

In Nature this week: comparison of five circulating tumor DNA assays, resequencing analysis of lettuce gives insight into its domestication, and more.